共 35 条
Exploring changes in placebo treatment arms in hidradenitis suppurativa randomized clinical trials: A systematic review
被引:18
作者:
Ali, Asma Amir
[1
]
Seng, Elizabeth K.
[2
,3
]
Alavi, Afsaneh
[4
]
Lowes, Michelle A.
[5
]
机构:
[1] Western Univ, Schulich Sch Med & Dent, London, ON, Canada
[2] Yeshiva Univ, Ferkauf Grad Sch Psychol, Bronx, NY USA
[3] Albert Einstein Coll Med, Saul R Korey Dept Neurol, Bronx, NY 10467 USA
[4] Univ Toronto, Womens Coll Hosp, Dept Med, Div Dermatol, Toronto, ON, Canada
[5] Rockefeller Univ, 1230 York Ave, New York, NY 10065 USA
关键词:
atopic dermatitis;
clinical outcomes;
clinical trial design;
Hawthorne effect;
hidradenitis suppurativa;
pain;
placebo response;
psoriasis;
2-PHASE;
3;
TRIALS;
DOUBLE-BLIND;
MODERATE;
ADALIMUMAB;
PREVALENCE;
DUPILUMAB;
EFFICACY;
THERAPY;
D O I:
10.1016/j.jaad.2019.05.065
中图分类号:
R75 [皮肤病学与性病学];
学科分类号:
100206 ;
摘要:
Background: Hidradenitis suppurativa (HS) is characterized by recurrent, painful nodules in flexural areas. Objective: The objective of this study was to explore the placebo response in HS randomized clinical trials and to compare it briefly with the placebo response in psoriasis and atopic dermatitis. Methods: A Cochrane Review on interventions in HS was used as a starting point, and a systematic review was then undertaken by using the PubMed database, yielding 7 HS randomized clinical trials for inclusion in this study. Results: This review demonstrates that there is a robust placebo response in HS that is most marked in physical signs but also marked in pain responses. Limitations: Multiple outcome measures utilized in these studies and reporting bias limited this review. Conclusion: This large placebo response has implications for clinical trial design. This knowledge can also help deliver improved clinical care by forming the basis of nonpharmacologic treatments and help optimize current medication use to maximize the placebo effect.
引用
收藏
页码:45 / 53
页数:9
相关论文